Navigation Links
Calcium linked to increased risk of heart disease and death in patients with kidney disease
Date:7/19/2013

TORONTO, ON, July 19, 2013 Kidney patients who take calcium supplements to lower their phosphorous levels may be at a 22 per cent higher risk of death than those who take other non-calcium based treatments, according to a new study by Women's College Hospital's Dr. Sophie Jamal.

The study, published today in the Lancet, calls into question the long-time practice of prescribing calcium to lower phosphate levels in patients with chronic kidney disease. The researchers suggest some of the calcium is absorbed into the blood stream and may expedite hardening of the arteries, leading to a higher risk of heart disease and even death. Cardiovascular disease is a leading cause of death for people with chronic kidney disease.

"Doctors commonly prescribe calcium supplements to prevent elevated phosphate levels, which can damage the body, but a growing number of studies have shown calcium supplements may actually increase the risk of heart disease," explains Dr. Sophie Jamal, a physician at Women's College Hospital and an associate professor of medicine at the University of Toronto. "Our study validates these claims and, for the first time, shows the long-term consequences of taking calcium supplements can be dangerous for patients with kidney disease."

As part of their analysis, researchers reviewed 11 randomized, controlled studies that included more than 4,600 patients. The researchers assessed the risk of heart disease, including heart attack, stroke, and hardening of the arteries, along with death among individuals prescribed the medication containing calcium and those prescribed the medication without calcium. They found:

  • A 22% reduction in death among patients who took non-calcium based treatments sevelamer and lanthanum.
  • Less artery calcification (hardening) in patients who did not take calcium supplements.

"Some researchers and physicians have been saying for years that kidney disease pa
'/>"/>

Contact: Magda Stec
magda.stec@wchospital.ca
416-323-6400 x3210
Women's College Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Calcium and vitamin D help hormones help bones
2. Magnesium may be as important to kids bone health as calcium
3. Calculating phosphorus and calcium concentrations in meat and bone meal for pig diets
4. Dysfunction in cerebellar Calcium channel causes motor disorders and epilepsy
5. Waste removal in worms reveals new mechanism to regulate calcium signaling
6. Hebrew University study finds key mechanism in calcium regulation
7. Community-based nutrition education shown to be successful in increasing calcium intake
8. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
9. Calcium supplements remain a valuable tool for maintaining bone health
10. New health-economic model shows benefits of boosting dietary calcium intake
11. Danish researchers release ground-breaking knowledge about calcium pumps in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a ... fight against a disease for which no vaccines are yet ... that this vaccination technique may be effective against HCV. The ... , The team, funded by the Canadian Institutes of ...
... and the Department of Horticulture in the College ... have developed a new procedure for the efficient ... of strawberry. The scientists have used Agrobacterium tumefaciens, ... woodland or alpine strawberry Fragaria vesca. , ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
Cached Biology News:U of S researchers develop new vaccine candidate against hepatitis C 2Strawberries by design 2Do plants have the potential to vaccinate against HIV? 2
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... non-toxic DCVax® personalized immune therapies for cancer, announced ... Loncar Cancer Immunotherapy Index (LCINDX), a professional index ... immunotherapy field within the biotechnology space.  ... 25 companies" in the immunotherapy space, including 6 ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Modality ... management systems for highly regulated industries, is pleased ... name a monthly columnist for Cold Chain IQ ... http://www.coldchainiq.com ). His column titled, Global Cold Chain ... information for today’s life sciences, pharmaceutical and healthcare ...
(Date:4/15/2015)... April 16, 2015 Immunocore ... drugs to treat cancer and other diseases, and ... of AstraZeneca, today announced that they have entered ... terms of the agreement, Immunocore will conduct a ... inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... DNDN ) today announced the Medicare Evidence ... of labeled and unlabeled use of PROVENGE® (sipuleucel-T) treatment ... This panel was convened as a part of the ... Centers for Medicare and Medicaid Services (CMS).   ...
... ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) ... CTI,s Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for ... children between the ages of six months and 18 ... EMA adopted an opinion agreeing to the PIP and ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 2European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 3
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: